Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03583138 · ClinicalTrials.gov registry record
HIV, Buprenorphine, and the Criminal Justice System (STRIDE2)
A clinical trial of Human Immunodeficiency Virus and Acquired Immunodeficiency Syndrome, sponsored by Yale University.
- Completed
- Registry status
- 159
- Enrollment target
- 1
- Study location
NCT03583138: Completed study of Human Immunodeficiency Virus and Acquired Immunodeficiency Syndrome, sponsored by Yale University.
NCT03583138 is a study of Human Immunodeficiency Virus and Acquired Immunodeficiency Syndrome that has completed, run by Yale University. The registered enrollment target is 159 participants, below the 180-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (12% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03583138, a study of Human Immunodeficiency Virus and Acquired Immunodeficiency Syndrome, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 159 participants
- Enrollment target
- 1
- Study location
Study Summary
STRIDE2 is a longitudinal, non-randomized study of individuals living with HIV who are dependent on opioids. This study is funded by the National Institute on Drug Abuse (R01DA030768, Altice, PI; Taxman \& Lawson, Co-PIs) and is being conducted by George Mason University, Yale University, and Howard University.
Primary Outcome
Blood test for HIV viral load
Conditions Studied
Interventions
- DRUG buprenorphine
Study Locations (1)
District of Columbia
- Howard University - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2014-06-23 |
| Est. Completion | 2017-06-30 |
What the finished NCT03583138 record still lists
NCT03583138 is an observational study that tracks outcomes without assigning an intervention. The registered 159 participants enrollment target is mid-sized for trials with a published cap, below the 180-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (12% lower).
The record links to 4 conditions, with Human Immunodeficiency Virus appearing as the primary indexed condition, and to 1 intervention - of which buprenorphine is the first listed.
NCT03583138 reports a single indexed study location in District of Columbia.
Frequently Asked Questions
What is clinical trial NCT03583138 about?
NCT03583138 is a clinical study titled "HIV, Buprenorphine, and the Criminal Justice System (STRIDE2)". STRIDE2 is a longitudinal, non-randomized study of individuals living with HIV who are dependent on opioids. This study is funded by the National Institute on Drug Abuse (R01DA030768, Altice, PI; Taxman \& Lawson, Co-PIs) and is being conducted by George Mason University, Yale University, and Howard...
What is the current status of trial NCT03583138?
This trial is currently completed. The enrollment target is 159 participants. The study started on 2014-06-23. Estimated completion is 2017-06-30.
What conditions does trial NCT03583138 study?
This clinical trial studies the following conditions: Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome, Drug Dependence, Opiate Addiction.
What interventions are being tested in trial NCT03583138?
The interventions under investigation include: buprenorphine (DRUG).
Who is sponsoring clinical trial NCT03583138?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03583138 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Immunodeficiency Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03583138's enrollment target sits among peer trials
159 12th of 39 higher than 28 of 39 other Human Immunodeficiency Virus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Human Immunodeficiency Virus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
-
Baricitinib for Reduction of HIV - CNS
RECRUITING · Phase 2
-
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
RECRUITING · Phase 2
-
Harm Reduction in HIV Primary Care for PLWH Who Use Drugs
RECRUITING
-
Tulane Abdominal Transplant Institute (TATI) of Solid Organ Transplantation of HIV-Positive Recipients From HIV-Positive Donors
RECRUITING
-
V+PSF-M for Tobacco Cessation in HIV Care in India
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05267626 · 159 participants · Phase 1
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- NCT06321575 · 159 participants · NA
The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)
- NCT06729151 · 159 participants
Effect of Intradetrusor onabotulinumtoxinA Injection Versus Conservative Management on Female Sexual Function in Patients With Bladder Pain Syndrome
- NCT07023731 · 159 participants · Phase 1
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI